Nuvectis Pharma prices $100 million public stock offering at $20 per share

Nuvectis Pharma, Inc. (Nasdaq: NVCT) entered into an underwriting agreement on June 29, 2026 with Cantor Fitzgerald & Co. as representative for a firm commitment public offering. Under the agreement, the Company agreed to sell to the Representative, in a firm commitment underwritten public offering, 5,000,000 shares of the Company's common stock, $0.00001 par value per share, at a price to the public of $20.00 per share, less underwriting discounts and commissions.¹

The underwriters also received an option, exercisable for 30 days, to purchase up to an additional 750,000 shares of Common Stock.¹ The transaction is expected to close on July 1, 2026, subject to the satisfaction of customary closing conditions.¹

Net proceeds to the Company are expected to be approximately $93 million, or approximately $107 million if the underwriters exercise their option to purchase the additional shares, after deducting underwriting discounts and commissions and estimated offering expenses.¹

Nuvectis said it intends to use the net proceeds from the offering to continue to advance the development programs of NXP100, NXP200, and NXP900 or any future product candidate, hiring of additional personnel, capital expenditures, costs of operating as a public company and other general corporate purposes.¹

The offering was conducted pursuant to the Company's effective shelf registration statement on Form S-3, filed with the SEC on February 13, 2026, as supplemented by a prospectus supplement dated June 29, 2026.¹ Per the prospectus supplement, Nuvectis common stock is listed on The Nasdaq Capital Market under the symbol NVCT, and on June 29, 2026, the last reported sale price was $28.53 per share.² The number of shares outstanding after the offering is based on 26,525,533 actual shares outstanding as of March 31, 2026.²